Clinical Trials on Non-Small Cell Lung Cancer, Ovarian Cancer

Total 16673 results

Vastra Gotaland Region

Not yet recruiting

Addition of Hypofractionated High Dose Radiation in Oligometastatic Disease (ANDROMEDA)

Non Small Cell Lung Cancer

Sweden
Sun Yat-sen University

Recruiting

The Impact of Thymosin α-1 on the Efficacy of Concurrent Chemoradiotherapy Followed by Immunotherpay Consolidation for Locally Advanced NSCLC

Non-small Cell Lung Cancer

China
3D Medicines (Sichuan) Co., Ltd.

Recruiting

Phase III Study of Envafolimab Versus Placebo Plus Chemotherapy in Resectable Stage III NSCLC

Non-small Cell Lung Cancer

China
Sichuan Baili Pharmaceutical Co., Ltd.

Not yet recruiting

A Study of BL-M07D1 in Patients With HER2-mutated, Locally Advanced or Metastatic Non-small-cell Lung Cancer

Non-small Cell Lung Cancer

China
Liaoning Tumor Hospital & Institute
Huazhong University of Science and Technology; LinkDoc Technology (Beijing)...

Not yet recruiting

Observational Study of Huaier Granules in Postoperative Adjuvant Therapy for Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

China
CellSight Technologies, Inc.
University of Iowa Hospitals & Clinics

Not yet recruiting

Test-retest Evaluation of [18F]F-AraG PET

Non-small Cell Lung Cancer

United States
Muhammad Furqan

Recruiting

Ascorbate With Durvalumab in Non-Small Cell Lung Cancer (NSCLC)

Non-small Cell Lung Cancer

United States
M.D. Anderson Cancer Center

Not yet recruiting

PhI/II Study of Amivantamab and Tepotinib Combo in MET-altered Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

United States
Shenzhen TargetRx, Inc.
Sun Yat-sen University

Recruiting

TGRX-326 Chinese Phase III for Advanced Non-small Cell Lung Cancer (NSCLC)

Non Small Cell Lung Cancer

China
Nanjing Sanhome Pharmaceutical, Co., Ltd.

Recruiting

SH-1028 Tablets Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB NSCLC With Sensitizing EGFR Mutations

Non-small Cell Lung Cancer

China
Merck Sharp & Dohme LLC
ModernaTX, Inc.

Recruiting

A Study of V940 Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)

Non-small Cell Lung Cancer

United States, New Zealand, Australia, Costa Rica, Taiwan, Argentina, France, Chile, Hungary, Spain
Memorial Sloan Kettering Cancer Center
EARLY Labs

Recruiting

Using Urine Samples to Identify Lung Cancer

Non Small Cell Lung Cancer

United States
Sichuan Baili Pharmaceutical Co., Ltd.

Recruiting

A Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer or Other Solid Tumors

Non-small Cell Lung Cancer

China
Dizal Pharmaceuticals

Recruiting

Assessing the Effect of DZD9008 on the Pharmacokinetics of the Cocktail Probes Representative for CYP3A4, P-gp, BCRP and OATP1B1 in Patients With EGFR or HER2 Mutant Advanced Non-small Cell Lung Cancer (WU-KONG19)

Non-small Cell Lung Cancer

China
AstraZeneca

Recruiting

Study to Assess Neoadjuvant Durvalumab (D) and Platinum-Based Chemotherapy (CT), Followed by Either Surgery and Adjuvant D or CRT and Consolidation D, in Resectable or Borderline Resectable Stage IIB-IIIB NSCLC (MDT-BRIDGE) (MDT-BRIDGE)

Non-small Cell Lung Cancer

Spain, Italy, France, Canada, Portugal, United States, Czechia, Germany, Sweden, Austria, Hungary
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

A Clinical Study of TQB2450 Injection Combined With Chemotherapy or Anlotinib Hydrochloride Capsule in the Treatment of Non Small Cell Lung Cancer

Non Small Cell Lung Cancer

China
Sichuan Kelun Pharmaceutical Research Institute...
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Recruiting

A Phase III Study of SKB264 for EGFR Mutant NSCLC Patients

Non-small Cell Lung Cancer

China
Centre hospitalier de l'Université de Montréal...

Recruiting

Dietary Intervention for NSCLC Patients Treated With ICI

Non Small Cell Lung Cancer

Canada
Transgene

Recruiting

A Clinical Trial of TG6050 in Patients With Metastatic Non-Small Cell Lung Cancer (Delivir)

Non-small Cell Lung Cancer

France
Peking Union Medical College Hospital

Recruiting

Phase II Clinical Study of Pyrotinib in First-line Treatment of Primary HER2-amplified/Mutated Advanced Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

China
OncoC4, Inc.
BioNTech SE

Recruiting

ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors (PRESERVE-003)

Non Small Cell Lung Cancer

United States, Belgium, Canada, France, Germany, Italy, Korea, Republic of, Spain, China, Netherlands, Turkey, United Kingdom, Australia
Dizal Pharmaceuticals

Recruiting

A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

China
Shanghai Proton and Heavy Ion Center

Recruiting

Carbon Ion Therapy for Peripheral Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

China
Chang Gung Memorial Hospital

Not yet recruiting

Mobile Health Application of Disease Self-Management in Non-Small Cell Lung Cancer Patients During Targeted Therapy

Non-small Cell Lung Cancer
AstraZeneca

Recruiting

Study to Assess the Efficacy and Safety of Adjuvant Osimertinib in NSCLC With Uncommon EGFRm

Non-small Cell Lung Cancer

China
Tianjin Medical University Cancer Institute and...

Recruiting

Study of Osimertinib+Bevacizumab+Chemotherapy for EGFR+ Advanced Non-Small Cell Lung Cancer With Concurrent Mutations

Non Small Cell Lung Cancer

China
Fuzhou General Hospital

Not yet recruiting

ctDNA as a Biomarker for Treatment in Advanced NSCLC

Non-small Cell Lung Cancer

China
Instituto Nacional de Cancerologia de Mexico

Recruiting

Metformin Plus Tyrosine Kinase Inhibitors for Treatment of Patients With Non-small Cell Lung Cancer With EGFR Mutations (METLUNG)

Non Small Cell Lung Cancer

Mexico
OBI Pharma, Inc

Recruiting

To Evaluate OBI-833/OBI-821 in Combination With First-Line Erlotinib in Patients With EGFR-Mutated, Globo H-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (EGFR)

Non-small Cell Lung Cancer

Taiwan
Yonsei University

Not yet recruiting

A Window of Opportunity Study for Investigating Drug Tolerant Persister (DTP) to Preoperative Brigatinib in Resectable Non-small Cell Lung Cancer (NSCLC) Harboring ALK Fusions.

Non-small Cell Lung Cancer

Korea, Republic of
Sichuan Kelun Pharmaceutical Research Institute...

Recruiting

SKB264 Combinatiton Therapy in Patients With Advanced or Metastatic Non-small Cell Lung Cancer.

Non-small Cell Lung Cancer

China
People's Hospital of Quzhou

Recruiting

Efficacy and Safety of Conventional and Low-dose Platinum Gemcitabine Combined With Cindilimab With Delayed Administration in First-line Treatment of Advanced Squamous Non-small Cell Lung Cancer

Non Small Cell Lung Cancer

China
Hunan Province Tumor Hospital

Recruiting

Efficacy and Biomarker Explanation of IBI-323 + Bevacizumab Plus Platinum Based Chemotherapy on ALK-Rearranged NSCLC

Non Small Cell Lung Cancer

China
Hunan Province Tumor Hospital

Recruiting

Atezolizumab Combined With Platinum-based Chemotherapy as Neoadjuvant Therapy for Patients With Resectable Stage II-IIIB

Non Small Cell Lung Cancer

China
OncoRadiomics
University Hospital, Antwerp

Not yet recruiting

Artificial Intelligence for Help Non-Small Cell Lung Cancer: Measure Cancer Biology and Treatment Response Via Imaging (SALMON)

Non Small Cell Lung Cancer
University Hospital Heidelberg
Ludwig-Maximilians - University of Munich; German Cancer Research Center; University...

Recruiting

Pulmonary Magnetic Resonance-guided Online Adaptive Radiotherapy of Locally Advanced Non-Small Cell Lung Cancer (PUMA)

Non-small Cell Lung Cancer

Germany
Yonsei University

Not yet recruiting

The Safety and Efficacy of First-line Lazertinib and Locally Ablative Radiotherapy in Patients With Synchronous Oligo-metastatic EGFR-mutant Non-small Cell Lung Cancer

Non Small Cell Lung Cancer

Korea, Republic of
Wuhan Union Hospital, China

Not yet recruiting

Salvage Surgery Following Downstaging of Advanced Non-small Cell Lung Cancer by Targeted Therapy (SDANT)

Non Small Cell Lung Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

A Clinical Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsules Versus K Drug in the Treatment of First-line Non-small Cell Lung Cancer(NSCLC)

Non Small Cell Lung Cancer

China
Wuhan Union Hospital, China

Recruiting

Neoadjuvant Immunotherapy and Chemotherapy Followed by Surgery in Unresectable Stage Ⅲ NSCLC (NEOSUN)

Non Small Cell Lung Cancer

China
Medical University Innsbruck
Merck Sharp & Dohme LLC

Recruiting

Trial Exploring Combined Neoadjuvant Therapy With Pembrolizumab/Lenvatinib + Adjuvant Pembrolizumab in Pat. With NSCLC (INNWOP1)

Non Small Cell Lung Cancer

Austria
National Health Research Institutes, Taiwan

Recruiting

The Research Plan of Taiwan Precision Medicine

Non-small-cell Lung Cancer

Taiwan
Tianjin Medical University Cancer Institute and...

Recruiting

Fluzoparib Combined With Camrelizumab for Maintenance Treatment of Locally Advanced Non-small Cell Lung Cancer (F&C)

Non-small Cell Lung Cancer

China
Shanghai Pulmonary Hospital, Shanghai, China

Recruiting

Neoadjuvant Durvalumab/Anlotinib /Chemotherapy Plus Curative Resection in Stage III Non-Small-Cell Lung Cancer : A Single-arm Phase II Study

Non Small Cell Lung Cancer

China
Peking Union Medical College Hospital
AstraZeneca

Recruiting

Mechanism of Response to IMFINZI Neoadjuvant Therapy in Non-small Cell Lung Cancer Patients Based on Multiple-omics Models

Non-small Cell Lung Cancer

China
Tianjin Medical University Cancer Institute and...

Not yet recruiting

Almonertinib as Upfront Treatment for Uncommon EGFR Mutation Harboring Non-Small-Cell Lung Cancer Patients: A Multicenter, Open-Label, Phase II Trial (AUTUMN)

Non Small Cell Lung Cancer

China
University of Leeds
University College London Hospitals; The Leeds Teaching Hospitals NHS Trust; University... and other collaborators

Recruiting

A Platform Study of Novel Agents in Combination With Radiotherapy in NSCLC (CONCORDE)

Non Small Cell Lung Cancer

United Kingdom
Hunan Province Tumor Hospital

Recruiting

Survival Outcome of EGFR-TKI in Uncommon EGFR Mutant Advanced NSCLC

Non-small Cell Lung Cancer

China
Hunan Province Tumor Hospital

Recruiting

Chemotherapy or Chemotherapy Plus PD-1 Antibody in RET Fusion Positive Advanced NSCLC Patitnts: the POSEIDON Trial (POSEIDON)

Non-small Cell Lung Cancer

China
Beijing Pearl Biotechnology Limited Liability Company

Recruiting

A Study of PLB1001 in Non-small Cell Lung Cancer With c-Met Dysregulation(KUNPENG) (KUNPENG)

Non-small Cell Lung Cancer

China

3

Subscribe